12/18/06 VGX Pharmaceuticals Announces an R&D and License Agreement with VGX International to Develop Novel Type 1 Diabetes Therapeutics
12/6/06 VGX Pharmaceuticals Announces Publication of Preclinical Efficacy Studies for VGX-1027 for Treating Type 1 Diabetes
11/14/06 VGX Pharmaceuticals Announces a License Agreement with Inovio Biomedical to Develop Novel Cancer Therapeutics
11/7/06 VGX-150 Animal Efficacy Study Featured in Molecular Therapy
10/27/06 VGX Pharmaceuticals Announces the Initiation of IND-enabling Toxicology Studies for VGX-1027
10/26/06 VGX Pharmaceuticals Announces New Product Marketing and Sales Plan for Asia and Other Developing Regions
10/18/06 VGX Pharmaceuticals Announces Management Promotions
10/16/06 VGX Pharmaceuticals Announces the Completion of Financial Audits
10/13/06 VGX Pharmaceuticals Completes Manufacturing of New Oncology Drug VGX-150 for Phase I Clinical Trials
9/27/06 VGX Collaborators Present at the ICAAC
9/22/06 VGX CEO named Among 50 Most Influential Men under 42
9/11/06 VGX Pharmaceuticals Announces Publication of Preclinical Animal Efficacy Studies for VGX-150 in Molecular Therapy
8/31/06 VGX Pharmaceuticals Announces the Initiation of IND-enabling Toxicology Studies for VGX-150
8/23/06 VGX Pharmaceuticals announced the appointment of Niranjan Y. Sardesai, Ph.D. as Senior Director, Product Development
8/8/06 VGX Pharmaceutical Announces Executive Resignation
7/25/06 VGX Pharmaceutical Announces Executive Promotions
7/17/06 VGX Pharmaceuticals Provides Update on Additional Phase II Clinical Trial for PICTOVIR™
7/1/06 VGX Pharmaceuticals Announced the Appointment of Jessica C. Lee as Director, Clinical Development
5/22/06 VGX Co-Founder and Chief Medical Officer to Chair Vaccine Discovery and Commercialization Conference
5/15/06 VGX Pharmaceuticals Announces a New Site Opening for Phase II Clinical Trials of VGX–410C for the Treatment of Chronic Hepatitis C Infection
5/1/06 VGX Announces Promotion of Gene Kim as Chief Financial Officer
4/28/06 VGX Pharmaceuticals Initiates Manufacturing of VGX-1027 for Phase I Clinical Trials
4/7/06 VGX Pharmaceuticals Announces FDA Acceptance of IND for PICTOVIR™
3/9/06 VGX Pharmaceuticals Announces IND Submission for Additional Phase II Clinical Trials for PICTOVIR™
2/28/06 VGX Pharmaceuticals and DowpharmaSM Sign Research and Development Agreement for VGX’s Lead Cancer Compound
2/22/06 VGX Pharmaceuticals Enters In-Licensing Agreement with Ganial Immunotherapeutics, Inc. for Novel Drug Compound for Inflammatory Diseases
1/9/06 J. JOSEPH KIM, Ph.D., has been Designated a Young Global Leader in 2006

 

  
 
© 2008 VGX™ Pharmaceuticals. All rights reserved.